Table S8.
Meta-analysis of ACR20 | Comparator | OR | Lower 95% CI | Upper 95% CI | P value |
---|---|---|---|---|---|
Direct | |||||
Tocilizumab 4 mg/kg/4 weeks | MTX | 2.279 | 1.034 | 5.02 | 0.041 |
Tocilizumab 4 mg/kg/4 weeks | Placebo | 10.558 | 3.859 | 28.885 | 0.000 |
Tocilizumab 8 mg/kg/4 weeks | MTX | 5.417 | 1.195 | 24.546 | 0.028 |
Tocilizumab 8 mg/kg/4 weeks | Placebo | 28.069 | 9.689 | 81.318 | 0.000 |
Indirect via DMARD | |||||
Tocilizumab 8 mg/kg/4 weeks | Tocilizumab 4 mg/kg/4 weeks | 2.377 | 0.432 | 13.084 | 0.320 |
Indirect via placebo | |||||
Tocilizumab 8 mg/kg/4 weeks | Tocilizumab 4 mg/kg/4 weeks | 2.659 | 0.615 | 11.498 | 0.191 |
Inconsistency on loop | 0.894 | 0.094 | 8.465 | 0.922 |
Abbreviations: OR, odds ratio; CI, confidence interval; MTX, methotrexate; DMARD, disease modifying anti-rheumatic drug.